Drug Development for Pediatric Populations: Regulatory Aspects. - Wikidata - awgldk - TriplyDB

Drug Development for Pediatric Populations: Regulatory Aspects.

Drug Development for Pediatric Populations: Regulatory Aspects.

http://www.wikidata.org/entity/Q37666706

about

Effect of propofol and remifentanil on cerebral perfusion and oxygenation in pigs: a systematic review Neonatal drug therapy: The first frontier of therapeutics for children Population pharmacokinetic analysis of oxaliplatin in adults and children identifies important covariates for dosing.Application of physiologically based pharmacokinetic modeling to predict acetaminophen metabolism and pharmacokinetics in children Approval status and evidence for WHO essential medicines for children in the United States, United Kingdom, and Japan: a cross-sectional study Novel formulation and drug delivery strategies for the treatment of pediatric poverty-related diseases.Applications of accelerator MS in pediatric drug evaluation.Challenges and considerations for development of therapeutic proteins in pediatric patients.Physiologically based pharmacokinetic and pharmacodynamic modeling in cancer drug development: status, potential and gaps.Neonatal medicines research: challenges and opportunities.Quantitative clinical pharmacology for size and age scaling in pediatric drug development: A systematic review.A Comprehensive Review of Novel Drug-Disease Models in Diabetes Drug Development.Population pharmacokinetic analysis of a nevirapine-based HIV-1 prevention of mother-to-child transmission program in Uganda to assess the impact of different dosing regimens for newborns.Model-based assessment of dosing strategies in children for monoclonal antibodies exhibiting target-mediated drug disposition Semi-Mechanistic Model for Predicting the Dosing Rate in Children and Neonates for Drugs Mainly Eliminated by Cytochrome Metabolism.Model Informed Pediatric Development Applied to Bilastine: Ontogenic PK Model Development, Dose Selection for First Time in Children and PK Study Design.Considerations for pediatric trial designs and analyses.Drugs Being Eliminated via the Same Pathway Will Not Always Require Similar Pediatric Dose Adjustments.Recommendations to Enhance Pediatric Cardiovascular Drug Development: Report of a Multi-Stakeholder Think Tank.Epinephrine in Anaphylaxis: Preclinical Study of Pharmacokinetics after Sublingual Administration of Taste-Masked Tablets for Potential Pediatric Use.

P2860

Q26743386-2D7BED66-2488-443F-B9D1-BB6F931E66FA Q27013749-E75B306E-18C7-4889-9B65-91C73F92FD37 Q35130636-462F8162-A4E0-4041-A8EB-B869A99CF6E1 Q37279407-E5913117-AEAD-438F-83C3-A1ADB16759C3 Q37566655-EB832FB5-33F4-4751-B298-E2B6D6164F47 Q37976848-B7AA5A96-9B0C-4506-979E-484724B201EC Q38040176-6B21A732-3E73-4CCC-99D6-F28130F708F3 Q38364457-5B99CE2E-C2B5-45EC-9388-043266638B5C Q38458340-0BAE6445-56E1-47DA-9B00-0FDE94E5238F Q38469763-55529917-895B-479C-99EE-82E1C7E187D9 Q38502414-EDE7A631-E5EC-4D31-870F-5A666EBC353A Q38707493-F0FA1890-C533-499E-8E7A-5CBE48FA1BF2 Q38865904-F86E4179-AB44-4AF2-A38F-5C83D2964BC5 Q41915506-C6AF646C-60F7-4A68-83F3-57FE5E731330 Q47826980-6BCE88F3-1EA6-4449-8367-B7BFE6AAADB7 Q47877945-DEA14CC9-FDCE-48CC-8513-1DF42CB5868A Q48034344-D542BA0F-CACD-455F-85B1-6F01004A3C0E Q49330212-BC3B7296-5A63-4290-9C81-C233263BBAC4 Q50027860-6F4E83FF-D7F4-4CC6-ABC5-0ED72682717E Q50034090-1215B6D7-F6EA-4BA2-BA17-A1CABCCC4C85

P2860

Drug Development for Pediatric Populations: Regulatory Aspects.

http://www.wikidata.org/entity/Q37666706

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

2010年學術文章

@zh

2010年學術文章

@zh-hant

name

Drug Development for Pediatric Populations: Regulatory Aspects.

@en

Drug Development for Pediatric Populations: Regulatory Aspects.

@nl

type

label

Drug Development for Pediatric Populations: Regulatory Aspects.

@en

Drug Development for Pediatric Populations: Regulatory Aspects.

@nl

prefLabel

Drug Development for Pediatric Populations: Regulatory Aspects.

@en

Drug Development for Pediatric Populations: Regulatory Aspects.

@nl

P1433

Q37666706-C1924291-C6C8-421C-9A45-47F702B66E45

P1476

Q37666706-1699387C-FE3D-4AD2-9ED8-A8C827C26F2B

P2093

Q37666706-0FE389CD-5546-4A10-813C-054A123079D2

Q37666706-C33C0486-3516-43F1-B6F6-2648AC24C06F

Q37666706-DB4B1C22-7A45-47B9-A1B1-28EDC6D12ADD

P2860

Q37666706-0551175D-F4F7-499D-A3DD-DD457FCE62DD

Q37666706-149E94BA-2EA8-4B07-905C-F5FF3BF30EDB

Q37666706-22D78C4A-6526-47C0-BA6F-B418357B06BD

Q37666706-45450328-2380-484F-A935-D311F7669B66

Q37666706-4C122D39-1F35-44C4-819B-B88B6FE6437C

Q37666706-58436EC6-0FD9-47C4-B90A-6F3E5835D547

Q37666706-587D3883-BA64-407E-8E12-588F5F5C7C83

Q37666706-6260F4A2-3C6C-4D4F-817D-8A7492AC6124

Q37666706-8D8B8D35-B5C0-4F9D-9C92-1D59DB6E8287

Q37666706-969C7E9B-C1BE-4E86-906C-548142FDF5D9

P304

Q37666706-254C7336-AD27-4088-8EE4-F4D134AECAE7

P31

Q37666706-D1DCE983-C232-489A-8CBE-682EC8DCA554

P356

Q37666706-528F4418-EFE5-42F2-8367-7CE0A4BB1E23

P433

Q37666706-7BA2E1B7-A960-4D14-A06C-D1C7E3AB2CAB

P478

Q37666706-CF67FBA3-F5DB-4333-8783-3FB930E6ED3C

P577

Q37666706-E6925BE9-7663-4A56-A3A5-468033479F16

P5875

Q37666706-F75CC6DF-E99B-44F6-A65A-086173278446

P698

Q37666706-CFA42C44-3297-4E27-BAE5-6A9FB62D4227

P932

Q37666706-8E342390-2A67-43B1-9AD9-BAB8016B3D0C

P356

PHARMACEUTICS2040364

P1433

P1476

Drug Development for Pediatric Populations: Regulatory Aspects.

@en

P2093

Andreas Krause

http://www.w3.org/2001/XMLSchema#string

Jasper Dingemanse

http://www.w3.org/2001/XMLSchema#string

Jochen Zisowsky

http://www.w3.org/2001/XMLSchema#string

P2860

Proposals for model-based paediatric medicinal development within the current European Union regulatory framework

2000 CDC Growth Charts for the United States: methods and development

Ontogeny of hepatic and renal systemic clearance pathways in infants: part I.

Prediction of drug disposition in infants and children by means of physiologically based pharmacokinetic (PBPK) modelling: theophylline and midazolam as model drugs.

A pragmatic approach to the design of population pharmacokinetic studies.

Population pharmacokinetic studies in pediatrics: issues in design and analysis.

Population clinical pharmacology of children: general principles.

Guidelines on paediatric dosing on the basis of developmental physiology and pharmacokinetic considerations.

Integrated pharmacokinetics and pharmacodynamics in drug development.

The in silico child: using simulation to guide pediatric drug development and manage pediatric pharmacotherapy.

P304

364-388

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3390/PHARMACEUTICS2040364

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P577

2010-11-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49586407

http://www.w3.org/2001/XMLSchema#string

P698

27721363

http://www.w3.org/2001/XMLSchema#string

P932

3967144

http://www.w3.org/2001/XMLSchema#string